FULVENAT 250 MG INJ. VIAL.

About

Fulvenat 250 mg Injection contains fulvestrant, an antineoplastic medication classified as an estrogen receptor antagonist. Estrogen, a female sex hormone, can contribute to the growth of certain types of breast cancer. This injection is used alone to treat postmenopausal women with estrogen receptor-positive breast cancer that is locally advanced or has spread to other parts of the body. It is also used in combination with other anticancer medicines to treat hormone receptor-positive, HER2-negative breast cancer in women with advanced or metastatic disease.

Do not use this injection if you are allergic to fulvestrant or any of its ingredients, are pregnant or breastfeeding, or have severe liver disease. Before starting treatment, inform your doctor if you have liver or kidney problems, bone disorders, bleeding conditions, or heart disease. Fulvenat 250 mg Injection is not recommended for use in children or adolescents under 18 years of age. Seek immediate medical attention if you experience allergic reactions such as swelling of the face, lips, tongue, or throat after receiving the injection.

Common side effects include pain or swelling at the injection site, elevated liver enzyme levels, nausea, headache, cough, fatigue, joint or muscle pain, hot flashes, hair thinning, and skin rashes. Your doctor may recommend regular blood tests during treatment. This medicine may increase the risk of bleeding and liver damage. Women of childbearing potential should use effective contraception during treatment and for two years after the final dose.

Uses

• Treat Hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer in postmenopausal women.

Directions for use

This medicine will be administered by your doctor or nurse. Please do not attempt to self-administer it.


Side effects

• Joint and muscle pain
• Backache, bone pain
• Weakness, tiredness
• Headache
• Cough, difficulty breathing
• Hot flushes
• Pain at the site of injection
• Changes in heart rhythm
• Severe neutropenia(decreased WBC)
• Liver failure, inflammation of liver
• Hypersensitivity reaction
• Swelling in the body
• Constipation, diarrhea
• Loss of appetite
• Nausea, vomiting
• Decreased RBC, WBC, and Platelets
• Infections

Safety Measures

Alcohol - Alcohol consumption is not recommended during treatment with Fulvenat 250 mg Injection, as it may reduce the effectiveness of the medication. Avoid alcohol while on this therapy.
Pregnancy - Fulvenat 250 mg Injection is unsafe during pregnancy, as it may harm the developing fetus. Inform your doctor if you are pregnant, suspect pregnancy, or plan to become pregnant. Effective contraception is required during treatment and for two years after the final dose.
Breastfeeding - Breastfeeding is not advised while receiving Fulvenat 250 mg Injection, as the drug may pass into breast milk in small amounts and could harm the baby.
Liver - Fulvenat 250 mg Injection is not safe for patients with severe liver disease. Dose adjustments may be required for those with moderate liver impairment. Inform your doctor of any liver conditions before starting treatment.
Kidney - Fulvenat 250 mg Injection has minimal known effects on the kidneys, but caution is advised in patients with kidney problems. Consult your doctor before use.

Disclaimer

Med E Hub is committed to delivering reliable, expert-reviewed information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.